Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Goal Directed Fluid Management , Pvi

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03956901
Recruitment Status : Recruiting
First Posted : May 21, 2019
Last Update Posted : May 29, 2019
Sponsor:
Information provided by (Responsible Party):
Güneş Özlem Yıldız, Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Brief Summary:
The first objective of this study is to compare the liberal fluid management (LFM) with PVI guided goal-directed fluid management (GDFM) in gynecologic oncologic cases in terms of controlled intraoperative fluid balance, blood lactate levels, hemodynamic parameters, and postoperative serum creatinine levels. 112 patients who are in ASA I-II-lll risk groups included in this prospective study.

Condition or disease Intervention/treatment Phase
Fluid Overload Other: pvi guided fluid management Not Applicable

Detailed Description:

Objectives: The first objective of the investigators's study was to compare the liberal fluid management (LFM) with PVI guided goal-directed fluid management (GDFM) in terms of controlled intraoperative fluid volume, surgical end-point fluid balance, blood lactate and serum creatinine levels.

The investigators's secondary purpose was to compare the effects of different fluid regimens on the postoperative kidney injury and the duration of hospital stay.

Methods: The study included 112 American Society of Anesthesiologists (ASA) grade I ,ll and lll patients, aged above 18 and undergoing elective gynecologic oncologic case . After premedication with 0.03 mg /kg i.v. midazolam, all patients were started an i.v. infusion of 500 mL 0.9 % NaCl until the end of anesthesia induction.

After the anesthesia induction, while 0.9 % NaCl at rate of 2 mL/kg/h was infused in PVI- guided GDFM group, a 250-mL bolus cyristalloid/kolloid injection was administered when PVI was higher than 13 % over 5 min. While 0.9 % NaCl at rate of 4- 8 mL/kg/h was infused in LFM group, a 250-ml bolus cyristalloid/ kolloid injection was administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg. In both groups, when MAP was still < 65 mmHg after fluid bolus infusion, 5 mg i.v. bolus ephedrine was administered. The data collected during intraoperative period, such as heart rate, MAP, arterial blood gas samples (Ph, arterial oxygen pressure (PaO2), arterial carbon dioxide pressure (PaCO2), HCO3 level, hemoglobin, blood lactate level) were recorded. Hemoglobin, Na, K, Cl, serum creatinine, blood lactate and serum albumin scores were measured preoperatively, and up to 24 hours postoperative.

In the first 24 hours after surgery, urine output, need for blood transfusion ,lokositoz,fever,stay in icu and length of hospital stay were recorded.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Peroperative and Postoperative Effects of Goal Directed Fluid Therapy in Gynecological Staging Surgery
Actual Study Start Date : April 8, 2019
Estimated Primary Completion Date : September 8, 2019
Estimated Study Completion Date : December 30, 2019

Arm Intervention/treatment
Experimental: Liberal Fluid Management
liberal fluid management: 500 ml bolus crystalloid after 4-8 ml/kg/h infusion during surgery total amount of crystalloid volume of fluid infused during gycnecologcy l surgery fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml cyristaloid/Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
Other: pvi guided fluid management

GDFM Group: 500 ml bolus crystalloid after

2 ml \ kg crystalloid infusion to be started

If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.

PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.

PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13.

Other Name: liberal guided

Experimental: pvi guided fluid management

GDFM Group: 500 ml bolus crystalloid after

2 ml \ kg crystalloid infusion to be started

If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.

PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.

PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13.

Other: pvi guided fluid management

GDFM Group: 500 ml bolus crystalloid after

2 ml \ kg crystalloid infusion to be started

If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.

PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.

PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13.

Other Name: liberal guided




Primary Outcome Measures :
  1. fluid management [ Time Frame: 3-4 hours ]
    total fluid given durin operation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Gynecological oncologic cases
  2. Patients over 18 years old
  3. ASA 1-2-3 patients

Exclusion Criteria:

  1. Patients with peripheral arterial disease
  2. Patients with non-sinus rhythm, arrhythmia, atrial fibrillation
  3. Patients with entry MAP <65 mmHg
  4. Patients with advanced renal and hepatic impairment
  5. Mental retarded and non-cooperative patients
  6. Patients with advanced heart failure, EF <30%
  7. Patients have massive bleeding in the perioperative period, need for massive transfusion
  8. Patients have acute pulmonary pathology
  9. Patients with anaphylaxis who developed a blood product reaction
  10. Patients who do not allow a tidal volume of 8ml / kg in a mechanical ventilator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03956901


Contacts
Layout table for location contacts
Contact: gunes ozlem MD yildiz, specialist +905303603749 drgunesim@hotmail.com
Contact: duygu md akyol, specialist 05447616034 duygu.aygun@saglik.gov.tr

Locations
Layout table for location information
Turkey
Bakırköy Dr sadi konuk Education hospital Recruiting
Istanbul, Turkey
Contact: güneş özlem yildiz    905303603749    drgunesim@hotmail.com   
Sponsors and Collaborators
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Investigators
Layout table for investigator information
Principal Investigator: güneş özlem yildiz bakırköy Dr. Sadi Konuk Education hospital

Layout table for additonal information
Responsible Party: Güneş Özlem Yıldız, principal investigator, Bakirkoy Dr. Sadi Konuk Research and Training Hospital
ClinicalTrials.gov Identifier: NCT03956901     History of Changes
Other Study ID Numbers: 2019/152
First Posted: May 21, 2019    Key Record Dates
Last Update Posted: May 29, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No